person · Reporting owner
Patton Stephana Eilene
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUTERA INCCUTR · Entity 82936 | Chief Legal Officer | February 13, 2025 | February 21, 2025 |
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | See Remarks | March 12, 2021 | March 15, 2021 |
| Lineage Cell Therapeutics, Inc.BTX · Entity 6045 | General Counsel & Secretary | December 18, 2018 | December 20, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUTERA INC
Report date February 13, 2025 · Filed February 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 77,216 |
Reported balance
After 2025-02-13 transaction · row 1
1 source rowRow 1 · 2025-02-13 · Tax withholding · Disposed 623 · Balance 77,216 F1: 1. Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 1,563 Restricted Stock Units vesting on February 13, 2025. Such withholding is required by the Company's 2019 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 1,563 Restricted Stock Units vesting on February 13, 2025. Such withholding is required by the Company's 2019 Equity Incentive Plan.
Eiger BioPharmaceuticals, Inc.
Report date March 12, 2021 · Filed March 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,948 |
Reported balance
After 2021-03-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-03-12 · Grant · Acquired 11,875 · Balance 17,948 F1: Represents shares underlying Restricted Stock Units award that will vest in three equal annual installments measured from March 12, 2021. F2: Includes 1,253 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on March 5, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2031-03-11 | Direct | 71,250 |
Reported balance
After 2021-03-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-12 · Grant · Acquired 71,250 · Balance 71,250 F3: The option vests in equal monthly installments over 48 months measured from March 12, 2021 subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying Restricted Stock Units award that will vest in three equal annual installments measured from March 12, 2021.
F2: Includes 1,253 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on March 5, 2021.
F3: The option vests in equal monthly installments over 48 months measured from March 12, 2021 subject to Reporting Person's continuous service status as of each such date.
Lineage Cell Therapeutics, Inc.
Report date December 18, 2018 · Filed December 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, no par valueSEC Table I · non-derivative | Direct | 34,485 |
Last balance in matching sequence
After 2018-12-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-12-18 · Exercise / conversion · Acquired 27,500 · Balance 43,995 F1: Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018. F2: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Row 2 · 2018-12-18 · Tax withholding · Disposed 9,510 · Balance 34,485 F3: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 27,500 RSUs, the grant of which was previously reported on a Form 8-K. F2: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 13,750 |
Reported balance
After 2018-12-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-18 · Exercise / conversion · Disposed 27,500 · Balance 13,750 F4: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, 50% of the RSUs vested on December 18, 2018, then the remaining 25% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018.
F2: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options.
F3: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 27,500 RSUs, the grant of which was previously reported on a Form 8-K.
F4: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, 50% of the RSUs vested on December 18, 2018, then the remaining 25% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2025 Filed Feb 21, 2025 13:43 UTC | CUTERA INC CUTR · Entity 82936 | Tax withholdingCOMMON STOCK | 623 | $0.42 | $260.79 |
DisclosureSEC source: 0001628280-25-007066 · wk-form4_1740163410.xml · nonDerivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,216 F1 · shares: 1. Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 1,563 Restricted Stock Units vesting on February 13, 2025. Such withholding is required by the Company's 2019 Equity Incentive Plan. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 16:25 UTC | CUTERA INC CUTR · Entity 82936 | Tax withholdingCOMMON STOCK | 2,161 | $0.36 | $767.37 |
DisclosureSEC source: 0001628280-24-048102 · wk-form4_1731705917.xml · nonDerivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,839 F1 · shares: 1. Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 6,250 Restricted Stock Units vesting on November 13, 2024. Such withholding is required by the Company's 2019 Equity Incentive Plan. Read SEC document |
| October 24, 2024 Filed Nov 5, 2024 16:10 UTC | CUTERA INC CUTR · Entity 82936 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001628280-24-045285 · wk-form4_1730841027.xml · derivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,500 Underlying: COMMON STOCK · 37,500 shares Expires 2031-10-23 F1 · derivative.exercise_date: The stock options vest 1/48 per month from October 24, 2024, subject to the Reporting Person continuing to be a service provider of the Company. F2 · derivative.expiration_date: The expiration date is subject to earlier expiration upon the termination of the Reporting Person's service with the Company. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:32 UTC | CUTERA INC CUTR · Entity 82936 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001628280-24-032154 · wk-form4_1721266345.xml · derivative · entry 6 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: COMMON STOCK · 55,000 shares Expires 2031-05-13 F2 · derivative.exercise_price: On July 15, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $1.54 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to the option shall vest 1/48 per month from April 25, 2024, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:32 UTC | CUTERA INC CUTR · Entity 82936 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001628280-24-032154 · wk-form4_1721266345.xml · derivative · entry 5 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 55,000 shares Expires 2031-05-13 F4 · derivative.exercise_date: The shares subject to the option shall vest 1/48 per month from April 25, 2024, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:32 UTC | CUTERA INC CUTR · Entity 82936 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001628280-24-032154 · wk-form4_1721266345.xml · derivative · entry 4 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: COMMON STOCK · 30,000 shares Expires 2031-03-06 F2 · derivative.exercise_price: On July 15, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $1.54 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: One-fourth of the shares subject to the option shall vest on November 13, 2024 and then 1/36 of the remaining shares subject to the option shall vest monthly thereafter, subject to the reporting person continuing to be a service provider through each such date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:32 UTC | CUTERA INC CUTR · Entity 82936 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001628280-24-032154 · wk-form4_1721266345.xml · derivative · entry 3 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 30,000 shares Expires 2031-03-06 F3 · derivative.exercise_date: One-fourth of the shares subject to the option shall vest on November 13, 2024 and then 1/36 of the remaining shares subject to the option shall vest monthly thereafter, subject to the reporting person continuing to be a service provider through each such date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:32 UTC | CUTERA INC CUTR · Entity 82936 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001628280-24-032154 · wk-form4_1721266345.xml · derivative · entry 2 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: COMMON STOCK · 25,000 shares Expires 2031-03-06 F2 · derivative.exercise_price: On July 15, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $1.54 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · derivative.exercise_date: 50% of the shares subject to the option shall vest on November 21, 2024 and then 1/24 monthly thereafter for 12 months, subject to the reporting person continuing to be a service provider through each such date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:32 UTC | CUTERA INC CUTR · Entity 82936 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001628280-24-032154 · wk-form4_1721266345.xml · derivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 25,000 shares Expires 2031-03-06 F1 · derivative.exercise_date: 50% of the shares subject to the option shall vest on November 21, 2024 and then 1/24 monthly thereafter for 12 months, subject to the reporting person continuing to be a service provider through each such date. Read SEC document |
| May 13, 2024 Filed May 14, 2024 18:18 UTC | CUTERA INC CUTR · Entity 82936 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001628280-24-023329 · wk-form4_1715725088.xml · derivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: COMMON STOCK · 55,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The stock options vest 1/48 per month from April 25, 2024, subject to the Reporting Person continuing to be a service provider of the Company. F2 · derivative.expiration_date: The expiration date is subject to earlier expiration upon the termination of the Reporting Person's service with the Company. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 17:51 UTC | CUTERA INC CUTR · Entity 82936 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001628280-24-010056 · wk-form4_1709938246.xml · derivative · entry 5 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: COMMON STOCK · 25,000 shares Expires 2031-03-06 F5 · derivative.exercise_date: 25,000 shares of the stock options will vest according to the following schedule: 50% of the shares subject to the option shall vest on November 21, 2024 and then 1/24 monthly thereafter for 12 months, subject to the reporting person continuing to be a service provider through each such date. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 17:51 UTC | CUTERA INC CUTR · Entity 82936 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001628280-24-010056 · wk-form4_1709938246.xml · derivative · entry 4 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: COMMON STOCK · 30,000 shares Expires 2031-03-06 F4 · derivative.exercise_date: 30,000 shares of the stock option will vest according to the following schedule: One-fourth of the shares subject to the option shall vest on November 13, 2024 and then 1/36 of the remaining shares subject to the option shall vest monthly thereafter, subject to the reporting person continuing to be a service provider through each such date. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 17:51 UTC | CUTERA INC CUTR · Entity 82936 | GrantCOMMON STOCK | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-010056 · wk-form4_1709938246.xml · nonDerivative · entry 3 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 F3 · shares: 30,000 shares of the securities represent performance stock unit awards (PSU) granted to the reporting person. Each PSU represents a contingent right to receive one share of Common Stock. A quantity equal to 25% of the shares shall become eligible for time-based vesting if the 30-calendar day trailing average of the Company's closing common stock price meets or exceeds $20.00 within four years of the grant date. Once the foregoing condition is attained, 25% of the award shall vest on the later of (i) the date such condition is attained or (ii) the commencement date plus one year, and then 1/12 of the remaining shares shall vast quarterly thereafter, subject to the reporting person continuing to be a service provider through each such date. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 17:51 UTC | CUTERA INC CUTR · Entity 82936 | GrantCOMMON STOCK | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-010056 · wk-form4_1709938246.xml · nonDerivative · entry 2 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F2 · shares: 25,000 shares of the securities represent performance stock unit awards (PSU) granted to the reporting person. Each PSU represents a contingent right to receive one share of Common Stock. A quantity equal to 25% of the shares shall become eligible for time-based vesting if the 30-calendar day trailing average of the Company's closing common stock price meets or exceeds $10.00 within four years of the grant date. Once the foregoing condition is attained, 25% of the award shall vest on the later of (i) the date such condition is attained or (ii) the commencement date plus one year, and then 1/12 of the remaining shares shall vast quarterly thereafter, subject to the reporting person continuing to be a service provider through each such date. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 17:51 UTC | CUTERA INC CUTR · Entity 82936 | GrantCOMMON STOCK | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-010056 · wk-form4_1709938246.xml · nonDerivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: 25,000 shares of the securities represent restricted stock units (RSUs) granted to the reporting person. Each RSU represents a contingent right to receive one share of Common Stock. 25% of the shares shall vest on November 13, 2024 and then 1/12 of the remaining shares shall vest quarterly thereafter, subject to the reporting person continuing to be a service provider through each such date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 19:36 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 71,250 | $0.00 Strike: $9.99 | $0.00 |
DisclosureSEC source: 0001209191-21-020591 · doc4.xml · derivative · entry 2 Patton Stephana Eilene · CIK 0001698237 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,250 Underlying: Common Stock · 71,250 shares Expires 2031-03-11 F3 · derivative.exercise_date: The option vests in equal monthly installments over 48 months measured from March 12, 2021 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 19:36 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 11,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020591 · doc4.xml · nonDerivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,948 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest in three equal annual installments measured from March 12, 2021. F2 · balance_after: Includes 1,253 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on March 5, 2021. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:30 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-20-018995 · doc4.xml · derivative · entry 2 Patton Stephana Eilene · CIK 0001698237 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-03-11 F2 · derivative.exercise_date: The option vests in equal monthly installments over 48 months measured from March 12, 2020 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 05, 2020 Filed Mar 13, 2020 17:30 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 820 | $7.31 | $5,994.20 |
DisclosureSEC source: 0001209191-20-018995 · doc4.xml · nonDerivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,820 F1 · shares: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 22, 2019 Filed Apr 22, 2019 21:31 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 1,000 | $11.03 | $11,030.00 |
DisclosureSEC source: 0001209191-19-025562 · doc4.xml · nonDerivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 21:46 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option ( Right to Buy) · Derivative | 90,000 | $0.00 Strike: $14.31 | $0.00 |
DisclosureSEC source: 0001209191-19-021277 · doc4.xml · derivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Shares · 90,000 shares Expires 2029-03-20 F1 · derivative.exercise_date: The option will vest as to 25% of the option shares on March 18, 2020 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 13:36 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 27,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063602 · doc4.xml · derivative · entry 3 Patton Stephana Eilene · CIK 0001698237 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Shares · 27,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, 50% of the RSUs vested on December 18, 2018, then the remaining 25% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. F4 · derivative.expiration_date: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, 50% of the RSUs vested on December 18, 2018, then the remaining 25% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 13:36 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 9,510 | $1.03 | $9,795.30 |
DisclosureSEC source: 0001209191-18-063602 · doc4.xml · nonDerivative · entry 2 Patton Stephana Eilene · CIK 0001698237 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,485 F3 · shares: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 27,500 RSUs, the grant of which was previously reported on a Form 8-K. F2 · balance_after: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 13:36 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063602 · doc4.xml · nonDerivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018. F2 · balance_after: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:19 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 13,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054593 · doc4.xml · derivative · entry 3 Patton Stephana Eilene · CIK 0001698237 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Shares · 13,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, then the remaining 75% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. F4 · derivative.expiration_date: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, then the remaining 75% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:19 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 4,755 | $2.22 | $10,556.10 |
DisclosureSEC source: 0001209191-18-054593 · doc4.xml · nonDerivative · entry 2 Patton Stephana Eilene · CIK 0001698237 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,495 F3 · shares: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 13,750 RSUs, the grant of which was previously reported on a Form 8-K. F2 · balance_after: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 22:19 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054593 · doc4.xml · nonDerivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018. F2 · balance_after: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 23:08 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 125,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-18-020733 · doc4.xml · derivative · entry 2 Patton Stephana Eilene · CIK 0001698237 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2028-03-14 F2 · derivative.exercise_date: One quarter of the options shall vest upon the completion of continuous service from the date of grant until February 1, 2019, and the balance of the options shall vest in 36 equal monthly installments, commencing on February 1, 2019, based upon continued service. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 00:43 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | PurchaseCommon Shares, no par value | 7,500 | $2.58 | $19,376.25 |
DisclosureSEC source: 0001209191-17-049882 · doc4.xml · nonDerivative · entry 1 Patton Stephana Eilene · CIK 0001698237 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.